Cargando…

Fatigue in neuromuscular disorders: focus on Guillain–Barré syndrome and Pompe disease

Fatigue accounts for an important part of the burden experienced by patients with neuromuscular disorders. Substantial high prevalence rates of fatigue are reported in a wide range of neuromuscular disorders, such as Guillain–Barré syndrome and Pompe disease. Fatigue can be subdivided into experienc...

Descripción completa

Detalles Bibliográficos
Autores principales:	de Vries, J. M., Hagemans, M. L. C., Bussmann, J. B. J., van der Ploeg, A. T., van Doorn, P. A.
Formato:	Texto
Lenguaje:	English
Publicado:	SP Birkhäuser Verlag Basel 2009
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2824125/ https://www.ncbi.nlm.nih.gov/pubmed/20196238 http://dx.doi.org/10.1007/s00018-009-0184-2

Ejemplares similares

Fatigue: an important feature of late-onset Pompe disease
por: Hagemans, M. L. C., et al.
Publicado: (2007)

Enzyme replacement therapy and fatigue in adults with Pompe disease
por: Güngör, Deniz, et al.
Publicado: (2013)

Survival and associated factors in 268 adults with Pompe disease prior to treatment with enzyme replacement therapy
por: Güngör, Deniz, et al.
Publicado: (2011)

The quick motor function test: a new tool to rate clinical severity and motor function in Pompe patients
por: van Capelle, Carine I., et al.
Publicado: (2011)

Hearing in adults with Pompe disease
por: van der Beek, Nadine A. M. E., et al.
Publicado: (2011)

Impact of enzyme replacement therapy on survival in adults with Pompe disease
por: Güngör, Deniz, et al.
Publicado: (2013)

Burden of illness of Pompe disease in patients only receiving supportive care
por: Kanters, Tim A., et al.
Publicado: (2011)

Phenotypical variation within 22 families with Pompe disease
por: Wens, Stephan C A, et al.
Publicado: (2013)

Impact of enzyme replacement therapy on survival in adults with Pompe disease: results from a prospective international observational study
por: Güngör, Deniz, et al.
Publicado: (2013)

IVIG Treatment and Prognosis in Guillain–Barré Syndrome
por: van Doorn, Pieter A., et al.
Publicado: (2010)

Facing acute neuromuscular diseases during COVID-19 pandemic: focus on Guillain–Barré syndrome
por: Galassi, Giuliana, et al.
Publicado: (2020)

Determination of pain and response to methylprednisolone in Guillain-Barré syndrome
por: Ruts, Liselotte, et al.
Publicado: (2007)

Association of Muscle Strength and Walking Performance in Adult Patients With Pompe Disease
por: Favejee, Marein M, et al.
Publicado: (2018)

Hospital Admissions, Transfers and Costs of Guillain-Barré Syndrome
por: van Leeuwen, Nikki, et al.
Publicado: (2016)

Tracheostomy or Not: Prediction of Prolonged Mechanical Ventilation in Guillain–Barré Syndrome
por: Walgaard, Christa, et al.
Publicado: (2016)

Diffusion tensor imaging of the brain in Pompe disease
por: van den Dorpel, Jan J. A., et al.
Publicado: (2022)

IVIg‐induced plasmablasts in patients with Guillain‐Barré syndrome
por: Brem, Maarten D., et al.
Publicado: (2018)

Effects of exercise training in 23 adults with Pompe disease receiving enzyme therapy
por: van den Berg, Linda, et al.
Publicado: (2013)

Clinical features and predictors for disease natural progression in adults with Pompe disease: a nationwide prospective observational study
por: van der Beek, Nadine AME, et al.
Publicado: (2012)

PAS-positive lymphocyte vacuoles can be used as diagnostic screening test for Pompe disease
por: Hagemans, Marloes L. C., et al.
Publicado: (2010)

Enzyme replacement therapy reduces the risk for wheelchair dependency in adult Pompe patients
por: van der Meijden, Jan C., et al.
Publicado: (2018)

Antibodies to Heteromeric Glycolipid Complexes in Guillain-Barré Syndrome
por: Rinaldi, Simon, et al.
Publicado: (2013)

Prevalence of fatigue in Guillain-Barre syndrome in neurological rehabilitation setting
por: Ranjani, Prajna, et al.
Publicado: (2014)

Is the brain involved in patients with late‐onset Pompe disease?
por: van den Dorpel, Jan J. A., et al.
Publicado: (2022)

Public support for neonatal screening for Pompe disease, a broad-phenotype condition
por: Weinreich, Stephanie Shifra, et al.
Publicado: (2012)

Minutes of the European POmpe Consortium (EPOC) Meeting March 27 to 28, 2015, Munich, Germany
por: Schoser, Benedikt, et al.
Publicado: (2015)

Safety and efficacy of exercise training in adults with Pompe disease: evalution of endurance, muscle strength and core stability before and after a 12 week training program
por: van den Berg, Linda E. M., et al.
Publicado: (2015)

Guillain-Barre syndrome and mood disorders
por: Neroutsos, Evangelos, et al.
Publicado: (2010)

Population Pharmacokinetic Modelling of Intravenous Immunoglobulin Treatment in Patients with Guillain–Barré Syndrome
por: Fokkink, Willem Jan R., et al.
Publicado: (2022)

Facial-muscle weakness, speech disorders and dysphagia are common in patients with classic infantile Pompe disease treated with enzyme therapy
por: van Gelder, C. M., et al.
Publicado: (2011)

MRI changes in diaphragmatic motion and curvature in Pompe disease over time
por: Harlaar, Laurike, et al.
Publicado: (2022)

The Pompe Registry: tracking Pompe disease symptoms in a broad patient population
por: Byrne, B, et al.
Publicado: (2008)

Chest MRI to diagnose early diaphragmatic weakness in Pompe disease
por: Harlaar, Laurike, et al.
Publicado: (2021)

Diagnosis and management of Guillain–Barré syndrome in ten steps
por: Leonhard, Sonja E., et al.
Publicado: (2019)

Lack of robust satellite cell activation and muscle regeneration during the progression of Pompe disease
por: Schaaf, Gerben J., et al.
Publicado: (2015)

Quantification of Diaphragm Mechanics in Pompe Disease Using Dynamic 3D MRI
por: Mogalle, Katja, et al.
Publicado: (2016)

Lung MRI and impairment of diaphragmatic function in Pompe disease
por: Wens, Stephan CA, et al.
Publicado: (2015)

Treatment guidelines for Guillain–Barré Syndrome
por: Meena, A. K., et al.
Publicado: (2011)

Can Campylobacter coli induce Guillain-Barré syndrome?
por: van Belkum, A., et al.
Publicado: (2008)

Distal muscle weakness is a common and early feature in long-term enzyme-treated classic infantile Pompe patients
por: van den Dorpel, J. J. A., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_gfcncc92aqcld47536ss04l2fa